ACTRN12624000017527尚未招募3 期
The effect of 12 weeks Melatonin administration on depressive symptoms in youth with major depressive disorders - A Randomised, Placebo-controlled, Double-blinded Trial.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 579
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 30 Years(—)
- 性别
- All
入选标准
- •Aged between 18 and 30 inclusive at the time of providing informed consent
- •Current MDD according to the Structured Clinical Interview for DSM-5 (SCID-5)
- •Quick Inventory of Depressive Symptomatology, Adolescent version, self-rated (QIDS-A-SR) score > 11, indicating moderate-to-severe MDD, within 14 days of the first treatment visit
- •Pittsburgh Sleep Quality Index score >5 (general sleep disturbance) and/or Epworth Sleepiness Scale score >10 (suggestive of hypersomnia) and/or self-reported delayed sleep phase (habitual bed-time between 02:00-06:00) or irregular sleep cycles
- •Ability to provide written informed consent (including both adequate intellectual capacity and fluency in the English language)
排除标准
- •History of psychosis or bipolar type I or II (assessed with SCID-5)
- •Use of any form of melatonin or melatonin agonist within six weeks of the first treatment visit
- •Self-reported significant impaired kidney/ liver function (i.e., liver/kidney disease diagnosed)
- •Self-reported autoimmune conditions (e.g. rheumatoid arthritis, post-organ transplant)
- •Risk of difficulty with blood collection (e.g., poor vein visibility, previous incidence of fainting/significant discomfort during blood collection)
- •Self-reported sleep, respiratory (e.g., sleep apnoea), neurological, or medical conditions that could contribute to sleep-wake dysfunction
- •Self-reported allergy to melatonin or Microcrystalline Cellulose
- •Self-reported pregnancy or breastfeeding
- •Recent initiation (past 3 months) of new medication
- •Presence of a substance use disorder of at least moderate severity (according to DSM-5) within the preceding 6 months
- •Acute suicidal behaviour (score of 6 on Comprehensive Assessment of At-Risk Mental States item 7.3)
- •Participation in another trial of a sleep or circadian therapy within one month of the trial commencing
- •Regular shift work within 60-days prior to entry into the study.
- •Recent transmeridian travel across two or more time zones in the past one month
研究者
相似试验
已完成
不适用
Effect of melatonin supplementation in treatment of women with polycystic ovary syndromeIRCT2017082733941N9Vice chancellor for research, Arak University of Medical Sciences60
已完成
不适用
Effect of melatonin supplementation in treatment of patients with polycystic ovary syndromeIRCT2017090533941N23Vice Chancellor for research of Shahid Beheshti University of Medical Sciences60
已完成
2 期
Effect of supplementation in treatment of Coronary Heart DiseaseIRCT2017051333941N1Kashan University of Medical Sciences60
已完成
不适用
Effect of melatonin supplementation in treatment of maintenance methadone treatment patientsAddiction.Mental and behavioural disorders due to multiple drug use and use of other psychoactive substancesIRCT2017072933551N3Vice chancellor for research, Kashan University of Medical Sciences60
已完成
不适用
A clinical study for evaluating the effects of long-term oral intake of lactic acid bacteria on intestinal flora in human subjects.JPRN-UMIN000034695House Wellness Foods Corporation Research and Development Institute30
